Actinogen Medical
Business Services · Australia · 11-50 Employees
View Company Info for Free
Overview
Headquarters
L 9/109 Pitt St Se 901, Sydney, New Sout...Phone Number
+61 289647401Website
www.actinogen.com.auRevenue
$6.5 MillionStock Symbol
ACWIndustry
ZI Rank: 1
Signal Type
Mar
Apr
May
Jun
Jul
Aug
ZI Rank
1
1
1
1
1
1
About Actinogen Medical
Actinogen Medical Limited, a biotechnology company, develops therapies for cognitive impairment associated with chronic neurological diseases in Australia. The company is developing Xanamem, a therapy for Alzheimer's disease, and cognitive impairment associated with schizophrenia, diabetes, and other disorders; and XanADu, which has completed Phase II clinical trials is a double-blind, randomized, and placebo-controlled study to assess the safety, tolerability, and efficacy of Xanamem in subjects with mild Alzheimer's disease. It is also developing XanaHES, a single blinded, central reader blinded, placebo-controlled, and dose escalation study of Xanamem to assess safety and tolerability in healthy elderly subjects. The company was formerly known as Actinogen Limited and changed its name to Actinogen Medical Limited in November 2015. Actinogen Medical Limited was incorporated in 1999 and is headquartered in Sydney, Australia.Explore more
Actinogen Medical Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Actinogen Medical your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Website visits: Recent activity has been detected on your website
Earning: See what the market has to say on Actinogen Medical recently announced quarterly report
Funding: Get notified immidiatlly once Actinogen Medical has new funding data
Check out if Actinogen Medical is spiking on competitors!
Click to see if Actinogen Medical had a recent Job posting/layoffs
Product Launch: Get notified when Actinogen Medical launches new products
Check if Actinogen Medical has recently received funding, and reach out quickly before it becomes old news!
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Congratulate Masked Content for being promoted to Masked Content at Actinogen Medical
Actinogen Medical, which may be a good buyer, showed buying intent in Masked Content Topic
Recommended Actions
Find VP level buyers at Actinogen Medical
Find 3 more new buyers
Compare Similar Companies to Actinogen Medical
Compare insights from companies similar to Actinogen Medical, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Actinogen Medical is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Actinogen Medical is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Actinogen Medical.
Actinogen Medical financials insights
Gather financial insights about Actinogen Medical, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2025
Other Financing Round
$13.8M
Actinogen Medical Tech Stack
A closer look at the technologies used by Actinogen Medical
Most Recent Scoops
Project
Laboratory Operations, Medical Research, Clinical Operations
Project
Product Development, Product Management, Governmental Affairs & Regulation, Pharmaceuticals, Regulations
Funding
Funding
Event
Product Marketing, Events, Learning & Development, Software, Bioengineering, Pharmaceuticals, Public Health, Field /Outside Sales, Field Marketing, Healthcare Technology, Patient Experience
New Hire
Executive Move
Executive Moves, New Hire
Actinogen Medical News & Media
Actinogen Medical targets November XanaMIA results highlighting strong June quarter
Actinogen Medical Ltd managing director and CEO Dr Stephen Gourlay talked with Proactive about the company’s June quarter progress, including preparations for the pivotal XanaMIA Alzheimer’s disease trial topline results expected in November 2026. Gourlay said the fully enrolled Phase 2b/3 trial remained on schedule, with treatment, follow-up and data-cleaning activities continuing across participating sites. He described the upcoming readout as “a potentially transformational event for the comXanamem proof-of-concept trial demonstrating anti-depressant activity published in the British Journal of Psychiatry
Ongoing Xanamem (emestedastat) Alzheimer’s disease pivotal trial progresses toward final results in November this year Ongoing Xanamem (emestedastat) Alzheimer’s disease pivotal trial progresses toward final results in November this yearActinogen receives positive EMA scientific advice aligned with prior FDA guidance for its Alzheimer’s disease program
XanaMIA randomized, pivotal trial of oral Xanamem 10 mg fully enrolled and remains on track for topline final results in November 2026 XanaMIA randomized, pivotal trial of oral Xanamem 10 mg fully enrolled and remains on track for topline final results in November 2026Actinogen commences open-label phase of XanaMIA Alzheimer’s trial and provides business update
Randomized phase of XanaMIA pivotal trial of oral Xanamem 10 mg remains on track for topline final results in November 2026 Randomized phase of XanaMIA pivotal trial of oral Xanamem 10 mg remains on track for topline final results in November 2026
Read more news
Top Business Services Companies
Top companies in United Kingdom by revenue
Frequently Asked Questions Regarding Actinogen Medical
Sign Up For FreeTo access detailed company insights
Actinogen Medical Limited, a biotechnology company, develops therapies for cognitive impairment associated with chronic neurological diseases in Australia. The company is developing Xanamem, a therapy for Alzheimer's disease, and cognitive impairment associated with schizophrenia, diabetes, and other disorders; and XanADu, which has completed Phase... Read More
